Biomedical Engineering
-
BME alumnus Ash Jayagopal named Chief Scientific Officer of Opus Genetics
Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, has announced a key appointment to its founding executive team. Ash Jayagopal has joined the company as Chief Scientific Officer. Ash Jayagopal Jayagopal, BE’03, MS’05, PhD’08, is a biomedical engineering graduate who also served as an… Read MoreOct. 21, 2021
-
New drug targets vascular inflammation, drastically improves vascular procedures’ long-term effectiveness
Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, has announced a key appointment to its founding executive team. Ash Jayagopal has joined the company as Chief Scientific Officer. Ash Jayagopal Jayagopal, BE’03, MS’05, PhD’08, is a biomedical engineering graduate who also served as an… Read MoreOct. 12, 2021
-
Two Vanderbilt biomedical engineers lead top academic societies in their fields
Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, has announced a key appointment to its founding executive team. Ash Jayagopal has joined the company as Chief Scientific Officer. Ash Jayagopal Jayagopal, BE’03, MS’05, PhD’08, is a biomedical engineering graduate who also served as an… Read MoreSep. 21, 2021
-
Cynthia Reinhart-King is president-elect of the Biomedical Engineering Society
Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, has announced a key appointment to its founding executive team. Ash Jayagopal has joined the company as Chief Scientific Officer. Ash Jayagopal Jayagopal, BE’03, MS’05, PhD’08, is a biomedical engineering graduate who also served as an… Read MoreSep. 20, 2021
-
Data science workshops open to Vanderbilt community
Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, has announced a key appointment to its founding executive team. Ash Jayagopal has joined the company as Chief Scientific Officer. Ash Jayagopal Jayagopal, BE’03, MS’05, PhD’08, is a biomedical engineering graduate who also served as an… Read MoreSep. 17, 2021
-
School of Engineering announces 14 faculty appointments
Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, has announced a key appointment to its founding executive team. Ash Jayagopal has joined the company as Chief Scientific Officer. Ash Jayagopal Jayagopal, BE’03, MS’05, PhD’08, is a biomedical engineering graduate who also served as an… Read MoreSep. 16, 2021
-
Vanderbilt Engineering is 36th in 2022 ‘U.S. News’ rankings
Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, has announced a key appointment to its founding executive team. Ash Jayagopal has joined the company as Chief Scientific Officer. Ash Jayagopal Jayagopal, BE’03, MS’05, PhD’08, is a biomedical engineering graduate who also served as an… Read MoreSep. 13, 2021
-
Team awarded $2.3 million NIH grant to evaluate new, more accurate ultrasound methods
Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, has announced a key appointment to its founding executive team. Ash Jayagopal has joined the company as Chief Scientific Officer. Ash Jayagopal Jayagopal, BE’03, MS’05, PhD’08, is a biomedical engineering graduate who also served as an… Read MoreSep. 9, 2021
-
$1.9 million NIH project to investigate effects of shear stress on cancer cells
Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, has announced a key appointment to its founding executive team. Ash Jayagopal has joined the company as Chief Scientific Officer. Ash Jayagopal Jayagopal, BE’03, MS’05, PhD’08, is a biomedical engineering graduate who also served as an… Read MoreSep. 9, 2021
-
Research Snapshot: BME team demonstrates potential for 1st clinically successful osteoarthritis drug
Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, has announced a key appointment to its founding executive team. Ash Jayagopal has joined the company as Chief Scientific Officer. Ash Jayagopal Jayagopal, BE’03, MS’05, PhD’08, is a biomedical engineering graduate who also served as an… Read MoreSep. 2, 2021